Search Results - "Maare, C."

Considerations for study design in the DAHANCA 35 trial of protons versus photons for head and neck cancer by Friborg, J., Jensen, K., Eriksen, J.G., Samsøe, E., Maare, C., Farhadi, M., Sibolt, P., Nielsen, M., Andersen, M., Holm, A.I.S., Skyt, P., Smulders, B., Johansen, J., Overgaard, J., Grau, C., Hansen, C.R.

“…•There is limited clinical data on proton radiotherapy in head and neck cancer patients.•There is no consensus on trial design or relevant endpoints.•The…”
Get full text

NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy by Hansen, C R, Friborg, J, Jensen, K, Samsøe, E, Johnsen, L, Zukauskaite, R, Grau, C, Maare, C, Johansen, J, Primdahl, H, Bratland, Å, Kristensen, C A, Andersen, M, Eriksen, J G, Overgaard, J

“…Prediction models using logistic regression may perform poorly in external patient cohorts. However, there is a need to standardize and validate models for…”
Get more information

Dosimetric and geometric evaluation of the use of deformable image registration in adaptive intensity-modulated radiotherapy for head-and-neck cancer by Eiland, R.B., Maare, C., Sjöström, D., Samsøe, E., Behrens, C.F.

“…The aim of this study was to carry out geometric and dosimetric evaluation of the usefulness of a deformable image registration algorithm utilized for adaptive…”
Get full text

OC-0371 A HYPOFRACTIONATED RADIOTHERAPY (HYFRT) SCHEDULE FOR PALLIATIVE TREATMENT OF HEAD AND NECK CANCER by Maare, C, Andersen, E, Samsøe, E, Bentzen, J

Get full text

OC-009: Update of the randomised phase III trial DAHANCA 19: Primary C-RT or RT and zalutumumab for squamous cell carcinomas of head and neck by Eriksen, J.G, Maare, C, Johansen, J, Primdahl, H, Evensen, J, Kristensen, C.A, Andersen, L.J, Overgaard, J

Get full text

PO-0666: High dose hypofractionated radiotherapy for treatment and palliation of head and neck cancer patients by Maare, C, Kjeldsen, R, Jensen, K, Andersen, M, Andersen, E, Johansen, J

Get full text

Evaluation of the EGFR-Inhibitor Zalutumumab Given With Primary Curative (Chemo)radiation Therapy to Patients With Squamous Cell Carcinoma of the Head and Neck: Results of the DAHANCA 19 Randomized Phase 3 Trial by Eriksen, J.G, Maare, C, Johansen, J, Primdahl, H, Evensen, J.F, Kristensen, C.A, Andersen, L.J, Overgaard, J

Get full text

Adaptive RT for Head-and-Neck Cancer: The Usefulness of Deformable Image Registration by Behrens, C.F, Eiland, R.B, Sjöström, D, Maare, C, Paulsen, R.R, Samsøe, E

Get full text

OC-0372: DAHANCA19: A randomized phase III study of primary (chemo-) radiotherapy and zalutumumab in head and neck carcinomas by Eriksen, J.G, Maare, C, Johansen, J, Primdahl, H, Evensen, J, Kristensen, C.A, Andersen, L.J, Overgaard, J

Get full text

PO-0893 DOSIMETRIC- AND GEOMETRIC EVALUATION OF ADAPTIVE H&N IMRT USING DEFORMABLE IMAGE REGISTRATION by Eiland, R.B, Behrens, C.F, Sjöström, D, Maare, C, Paulsen, R.R, Samsoe, E

Get full text

PH-0489 How can we predict permanent xerostomia after radiotherapy in patients with head and neck cancer? by Bruvo, M., Pedersen, A.M.L., Samsøe, E., Maare, C., Mahmood, F.

Get full text

OC-0589 Barriers for inclusion in a proton therapy trial among Danish patients with head and neck cancer by Kristensen, A., Friborg, J., Jensen, K., Eriksen, J.G., Maare, C., Farhadi, M., Johansen, J., Hansen, C.R., Andersen, M., Dalton, S., Grau, C.

Get full text

EP-1695: Intra-treatment diffusion MRI for predicting radiotherapy response in head and neck cancer patients by Samsøe, E., Mahmood, F., Johannesen, H.H., Maare, C., Hansen, R.H.

Get full text

MO-0715 Tumor volume and cancer stem cells as prognostic markers for loco-regional control in HNSCC by Kristensen, M.H., Alsner, J., Sørensen, B.S., Hansen, C.R., Zukauskaite, R., Samsøe, E., Maare, C., Johansen, J., Primdahl, H., Bratland, A., Kristensen, C.A., Andersen, M., Lilja-Fischer, J.K., Tramm, T., Overgaard, J., Eriksen, J.G.

Get full text

OC-0118 First results on DAHANCA automatic segmentation algorithms of organs at risk by Lorenzen, E.L., Zukauskaite, R., Kyndt, M., Eriksen, J.G., Sarup, N., Johansen, J., Maare, C., Primdahl, H., Bratland, Å., Kristensen, C.A., Andersen, M., Overgaard, J., Brink, C., Rønn Hansen, C.

Get full text

MO-0713 Inter-expert observer variance of organs at risk according to the DAHANCA guidelines by Jensen, K., Lorentzen, E., Eriksen, J.G., Johansen, J., Gyldenkerne, N., Zukauskaite, R., Kjellgren, M., Andersen, E., Maare, C., Lønkvist, C.K., Nowicka-Matus, K., Szejniuk, W., Farhadi, M., Ujmajuridze, Z., Marienhagen, K., Johansen, T.S., Kristensen, B.S., Friborg, J., Overgaard, J., Hansen, C.R.

Get full text

PH-0048 Pattern of failure after curative (C-)RT in HNSCC: data from the phase III DAHANCA19 study by Kristensen, M.H., Hansen, C.R., Zukauskaite, R., Holm, A.I.S., Hinsby, E.S., Maare, C., Johansen, J., Primdahl, H., Bratland, Å., Christensen, C.A., Andersen, M., Overgaard, J., Eriksen, J.G.

Get full text

OC-0435 Loco-regional failure is associated with the stem cell marker SLC3A2, volume and HPV/p16 in HNSCC by Kristensen, M.H., Sørensen, B.S., Alsner, J., Hansen, C.R., Zukauskaite, R., Hinsby, E.S., Maare, C., Johansen, J., Primdahl, H., Christensen, C.A., Andersen, M., Lilja-Fischer, J., Tramm, T., Overgaard, J., Eriksen, J.G.

Get full text

OC-0271: 5-Y update of the randomized phase III trial DAHANCA19: Primary (Chemo) RT +/- zalutumumab in HNSCC by Eriksen, J.G., Maare, C., Johansen, J., Primdahl, H., Evensen, J., Kristensen, C.A., Andersen, L.J., Overgaard, J.

Get full text

EP-1172 Microstructural and physiological changes of parotid glands after RT for head and neck cancer by Bruvo, M., Behrens, C., Hvass, R., Hjorth Johannesen, H., Lynge Pedersen, A.M., Maare, C., Samsoee, E., Mahmood, F.

Get full text